Corporate dealmaking dominates the morning's agenda, headlined by Vodafone's fibre financing move in Germany and a £1.64 billion private equity swoop on Bodycote. Elsewhere, Bunzl lifted its outlook and launched a fresh buyback, AstraZeneca closed a $1.5 billion oncology licensing deal and posted positive trial data, and a bidding war for Capricorn Energy concluded with a topping bid from Norway's DNO.
Vodafone brings in Societe Generale as OXG fibre partner
Vodafone Group (LSE:VOD) has agreed to bring in Societe Generale as a 50% shareholder in OXG Glasfaser Beteiligungs-GmbH, its German fibre broadband joint venture, with the French bank acquiring the stake from Geodesia Holding S.à r.l. OXG builds and operates fibre infrastructure across Germany as part of Vodafone's drive to widen fixed-line coverage in the country, one of its largest and most fixed-line-underdeveloped markets in Europe.
The transaction installs a committed funding partner for OXG's continued network rollout while Vodafone retains strategic flexibility over the venture's direction. Financial terms were not disclosed, and the deal remains subject to customary regulatory approvals and closing conditions before it completes.
"This is a refinancing of OXG's ownership structure rather than a new venture or material acquisition."
The structure points to a capital-light approach to funding fibre expansion, offloading half the equity risk while keeping Vodafone in control of strategy. Without disclosed terms or clarity on OXG's scale relative to Vodafone's balance sheet, the deal's effect on group leverage is difficult to quantify, but it underlines Vodafone's continued commitment to German fixed-line infrastructure as a pillar of its wider network strategy.
Bodycote agrees £1.64 billion takeover by Veritas Capital
Bodycote (LSE:BOY) has agreed a recommended cash acquisition by Vulcan Alpha Bidco, a vehicle backed by New York private investment firm Veritas Capital. The world's largest provider of heat treatment and specialist thermal processing services, Bodycote runs around 130 facilities across 22 countries with around 4,000 employees, serving aerospace, automotive, energy and industrial customers.
Shareholders will receive 940p per share in total value, comprising 932.8p in cash plus a 7.2p interim dividend they retain in full. The cash consideration values Bodycote's equity at approximately £1.64 billion and implies an enterprise value of around £1.84 billion, representing a 36.5% premium to the three-month volume-weighted average price before press speculation triggered the offer period in May, and a 44% premium to the price the day before Veritas first approached the board in July. The agreed deal follows a competitive process in which rival private equity firm CVC also submitted a bid.
The outcome hands Bodycote's board a clean exit at a substantial premium and removes a long-running takeover overhang, while signalling continued private equity appetite for industrial services businesses with global manufacturing exposure.
Bunzl raises 2026 outlook, launches £500 million buyback
Bunzl (LSE:BNZL) reported revenue of £5.93 billion for the six months to 30 June, up 2.9% at constant exchange rates, with underlying revenue growth of 3.2%. The specialist international distribution and services group said adjusted operating profit rose 8.0% at constant exchange rates to £440.6 million, while operating margin expanded from 7.0% to 7.3%, aided by inflation-driven pricing and the annualisation of synergies from its Nisbets acquisition.
Adjusted earnings per share increased 11.4%, and the interim dividend rose 3.0%. North America Distribution, Bunzl's largest business, delivered 8% underlying revenue growth, supported by new customer wins secured in the second half of 2025 and restored service levels following operational fixes. "Bunzl has delivered a strong financial performance in the first half of 2026, with underlying growth in all regions and margin expansion," said Frank van Zanten, chief executive.
The combination of margin expansion, double-digit earnings growth and a £500 million buyback signals confidence in the durability of pricing gains and the North American recovery, reinforcing the group's raised outlook for the full year.
AstraZeneca completes $1.5 billion Zegfrovy licence deal with Dizal
AstraZeneca (LSE:AZN) has completed its previously announced exclusive licence agreement with Dizal Pharmaceutical Co., acquiring worldwide rights to develop and commercialise Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for non-small cell lung cancer, which accounts for 80-85% of lung cancer cases.
AstraZeneca will pay Dizal $600 million upfront, plus up to $900 million tied to development, regulatory and sales milestones, alongside tiered royalties on global Zegfrovy sales. The company said the transaction does not affect its 2026 financial guidance. Zegfrovy is already approved in the US and China for patients with EGFR exon 20 insertion mutation-positive NSCLC whose disease progressed after platinum-based chemotherapy, and a supplemental application for first-line use has been accepted by the FDA, backed by positive Phase III data from the WU-KONG28 trial.
The deal deepens AstraZeneca's lung cancer franchise beyond Tagrisso, adding a differentiated asset with a clear regulatory pathway already established in two major markets, and positions the company to compete more broadly across EGFR-mutated disease subtypes.
DNO trumps Genel with $396 million cash bid for Capricorn Energy
Norwegian oil and gas group DNO has agreed a recommended cash offer for Capricorn Energy (LSE:CNE) worth $5.214 a share, topping a rival bid from Genel Energy and securing Capricorn's board recommendation. The offer values Capricorn at approximately $396 million.
The agreement brings to a close a competitive bidding process between two established regional players, with DNO's higher cash offer winning out over Genel's proposal and consolidating ownership of Capricorn's asset base under the Norwegian group.
AstraZeneca's Tagrisso-Orpathys combo hits goal in first-line lung cancer trial
The Phase III SANOVO trial showed AstraZeneca (LSE:AZN)'s Tagrisso plus Orpathys combination significantly improved progression-free survival in treatment-naïve, MET-overexpressing EGFR-mutated lung cancer patients, extending the combination's reach into first-line treatment.
The result broadens the potential patient population for Tagrisso, AstraZeneca's leading lung cancer therapy, by validating its use alongside Orpathys earlier in the treatment pathway rather than only after disease progression.
GSK flu vaccine moves to Phase III after strong Phase II data
GSK (LSE:GSK) will start Phase III trials in September for its mRNA flu vaccine after early data showed stronger immune responses than existing licensed shots.
Advancing to late-stage trials keeps GSK in contention in the mRNA vaccine race, an area where competitors have pushed hard following the pandemic-era acceleration of mRNA technology, with flu representing a large recurring commercial market.
Frasers Group targets majority stake in Hugo Boss
Frasers Group (LSE:FRAS) said it now intends to build its Hugo Boss holding above 50% of the German fashion house's share capital and voting rights.
The move marks an escalation from Frasers' existing minority position and signals an intent to secure effective control of Hugo Boss, extending the retailer's pattern of building strategic stakes in branded fashion businesses.
Transense torque tech flies in Unison hybrid-electric demo
Transense Technologies (LSE:TRT)'s SAWsense torque sensors featured in Unison's hybrid-electric propulsion system, used in the first hybrid-electric flight above 30,000 feet and the first hybrid-electric transatlantic crossing.
The milestone flights provide a high-profile proof point for Transense's sensor technology in an emerging aerospace propulsion category, potentially opening further application opportunities as hybrid-electric aviation programmes advance toward commercialisation.
